Literature DB >> 33211356

A nationwide study on inpatient opportunistic infections in patients with chronic lymphocytic leukemia in the pre-ibrutinib era.

Vilhjálmur Steingrímsson1, Gauti Kjartan Gíslason1, Sigrún Þorsteinsdóttir1, Saemundur Rögnvaldsson1, Magnús Gottfreðsson1,2, Thor Aspelund3, Ingemar Turesson4, Magnus Björkholm5, Ola Landgren6, Sigurdur Y Kristinsson1,5.   

Abstract

OBJECTIVE: Opportunistic infections in chronic lymphocytic leukemia (CLL) have been described in clinical trials, single-center studies, and case reports. We performed a nationwide study to estimate the incidence and impact of inpatient opportunistic infections.
METHODS: The incidence rate (IR) and incidence rate ratio (IRR) for Swedish CLL patients diagnosed 1994-2013, and matched controls were calculated, as well as the case-fatality ratio (CFR).
RESULTS: Among 8989 CLL patients, a total of 829 opportunistic infections were registered (IR 16.6 per 1000 person-years) compared with 252 opportunistic infections in 34 283 matched controls (IR 0.99). The highest incidence in the CLL cohort was for Pneumocystis pneumonia (200 infections, IR 4.03); Herpes zoster (146 infections, IR 2.94), and Pseudomonas (83 infections, IR 1.66) infections. The highest risk relative to matched controls was observed for Pneumocystis pneumonia (IRR 114, 95% confidence interval 58.7-252). The 60-day CFR for CLL patients with opportunistic infections was 23% (188/821), highest for progressive multifocal encephalopathy (5/7, 71%) and aspergillosis (25/60, 42%).
CONCLUSION: We have uniquely depicted the incidence of rare and serious infections in CLL patients and found a relatively high incidence of Pneumocystis pneumonia. Of the most common opportunistic infections, CLL patients with aspergillosis had the poorest prognosis.
© 2020 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.

Entities:  

Keywords:  chronic lymphocytic leukemia; immunology and infectious diseases; lymphoproliferative diseases

Mesh:

Substances:

Year:  2020        PMID: 33211356     DOI: 10.1111/ejh.13553

Source DB:  PubMed          Journal:  Eur J Haematol        ISSN: 0902-4441            Impact factor:   2.997


  3 in total

1.  Management of herpesvirus reactivations in patients with solid tumours and hematologic malignancies: update of the Guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society for Hematology and Medical Oncology (DGHO) on herpes simplex virus type 1, herpes simplex virus type 2, and varicella zoster virus.

Authors:  Larissa Henze; Christoph Buhl; Michael Sandherr; Oliver A Cornely; Werner J Heinz; Yascha Khodamoradi; Til Ramon Kiderlen; Philipp Koehler; Alrun Seidler; Rosanne Sprute; Martin Schmidt-Hieber; Marie von Lilienfeld-Toal
Journal:  Ann Hematol       Date:  2022-01-07       Impact factor: 3.673

2.  BTK inhibitors impair humoral and cellular responses to recombinant zoster vaccine in CLL.

Authors:  Christopher Pleyer; Kerry J Laing; Mir A Ali; Christopher L McClurkan; Susan Soto; Inhye E Ahn; Pia Nierman; Emeline Maddux; Jennifer Lotter; Jeanine Superata; Xin Tian; Adrian Wiestner; Jeffrey I Cohen; David M Koelle; Clare Sun
Journal:  Blood Adv       Date:  2022-03-22

3.  Fatal Powassan virus encephalitis in patients with chronic lymphocytic leukemia.

Authors:  Isla M Johnson; Caleb Scheckel; Sameer A Parikh; Mark Enzler; Jennifer Fugate; Timothy G Call
Journal:  Blood Cancer J       Date:  2022-10-07       Impact factor: 9.812

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.